Restoration of the somatotropic axis with preserved pulsatility (P 800 cumulative) Tesamorelin Chemical Identity Stabilized synthetic analogue of human GHRH (44 amino acids) Tesamorelin Clinical Tolerability Safety profile evaluated in Phase III clinical trials in humans Published Clinical Data Phase III randomized controlled clinical trials published in NEJM and JAMA 15.2% Reduction of visceral adipose tissue at 26 weeks (2 mg SC/day vs placebo) Results at 26 Weeks 18% Reduction of visceral and hepatic fat at 12 months 12-Month Results Important Notice Search Only Not intended for human consumption
Learn More Long-acting amylin analogue that slows gastric emptying and reduces caloric intake
because it lacks the Drug Affinity Complex (DAC) albumin-binding moiety, it remains short-acting
This study directly compared the bioenergetics of peripheral blood lymphocytes in 25 healthy controls, 27 ME/CFS patients, and 20 Long COVID patients
Moreover, in facing various pathological challenges, the mammalian heart, which possesses high levels of mitochondria and weak antioxidant capacity, is susceptible to oxidant production and oxidative damage
Long-term success depends on individualized dosing, lifestyle factors, and ongoing provider guidance
